论文部分内容阅读
目的对痰热清注射液与头孢哌酮舒巴坦治疗小儿支气管肺炎疗效比较的文献资料进行系统评价,为临床用药提供参考。方法通过全面检索国内外已公开发表的与痰热清注射液治疗小儿支气管肺炎相关的随机对照临床试验研究文献,主要以小儿支气管肺炎的总有效率和临床症状体征缓解时间作为评价指标,并运用Cochrane协作网提供的软件RevMan5.1对纳入文献进行质量评价及Meta分析。结果 7篇公开发表文献符合纳入标准,共761例患儿。所有文献均为Jadad评分小于2分的低质量研究。Meta分析结果显示痰热清注射联合头孢哌酮舒巴坦治疗小儿支气管肺炎总有效率优于单纯使用头孢哌酮舒巴坦,总有效率比较OR值为4.99,95%可信区间为2.71~9.17;治疗组退热时间、咳嗽消失时间、肺部罗音消失时间均短于对照组,差异有统计学意义,OR值及95%可信区间分别为(OR=-0.95,95%CI=-1.15~-1.76)、(OR=-0.66,95%CI=-1.00~-0.32)和(OR=-0.94,95%CI=-1.21~-0.67)。结论痰热清注射液联合头孢哌酮舒巴坦治疗小儿支气管肺炎可能比单一使用头孢哌酮舒巴坦治疗取得更好的效果,且安全性良好。
OBJECTIVE: To systematically evaluate the literature on the therapeutic effects of Tanreqing injection and cefoperazone sulbactam in children with bronchopneumonia, and to provide a reference for clinical use. Methods The literature about randomized controlled clinical trials related to the treatment of pediatric bronchopneumonia with Tanreqing injection at home and abroad was comprehensively searched. The total effective rate of children with bronchial pneumonia and the symptom relief time of clinical symptoms were used as evaluation indexes. Cochrane Collaboration software provided RevMan5.1 quality evaluation of included literature and meta-analysis. Results Seven published articles met the inclusion criteria of 761 children. All references are low-quality studies with a Jadad score of less than 2 points. Meta analysis showed that Tanreqing injection combined with cefoperazone sulbactam treatment of children with bronchopneumonia total effective rate than the simple use of cefoperazone sulbactam, the total effective rate was 4.99,95%, the confidence interval was 2.71 ~ 9.17; The treatment group fever time, cough disappear time, lung rales disappear time are shorter than the control group, the difference was statistically significant, OR and 95% confidence interval were (OR = -0.95,95% CI = -1.15 ~ -1.76) (OR = -0.66, 95% CI = -1.00 ~ -0.32) and (OR = -0.94, 95% CI = -1.21 ~ -0.67). Conclusion Tanreqing injection combined with cefoperazone sulbactam treatment of children with bronchial pneumonia may be better than the single use of cefoperazone sulbactam treatment achieved better results, and good safety.